Tesofensine Drug Asset Due Diligence Report 2026

This Tesofensine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Discontinued

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Tesofensine can convert its Small molecule drug profile and DAT x NET x SERT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tesofensine (query alias: tesofensine)
Modality / target	Small molecule drug; DAT x NET x SERT; DAT antagonists, NET inhibitors, SERT inhibitors
Highest global status	Discontinued
Originator	NTG Nordic Transport Group A/S
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-UMIN000054277	Phase 3	Complete: follow-up complete	372	1. Mean change in absolute and percentage body weight after 24 weeks of treatment 2. Proportion of drug-related adverse events after 24 weeks of treatment
EUCTR2021-000146-18-SE	Phase 2	Not Recruiting	104	The primary efficacy endpoint of this study is the change in body weight (%) from Baseline to Week 36. Safety endpoints for the double-blind period include the following: • The incidence of TEAEs of special interest, including specified cardiovascular events, or specified psychiatric events; • The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); • The incidence of MACE; • Laboratory evaluation (chemistry and hematology) results at Baseline and at all site visits; • Vital sign measurements at Baseline and at Weeks 8, 16, 24, and 36; • ECG assessments at Baseline and at Weeks 8, 16, 24, and 36; • Holter monitoring at Screening and at Weeks 12 and 36; • Physical examination findings at Baseline and at Weeks 8, 16, 24, and 36; • C-SSRS administered by a trained rater at Baseline and at all visits; and • Patient Health Questionnaire-9 (PHQ-9) self administered by the subject at Baseline and at all visits.
EUCTR2016-003694-18-CZ	Phase 2	Completed	35	The primary endpoint for this study is percent change from baseline to end of treatment periods in mean body weight.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tesofensine addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2014-10-29	Saniona acquires clinical obesity asset from NeuroSearch	Phase 2	Financial terms not disclosed
2003-01-01	Boehringer Ingelheim and NeuroSearch Announce Exclusive Licensing Agreement for NS2330	Not disclosed	US$20.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Tesofensine for reduction of body weight in prader-willi patients”. The milestone feed surfaced a patent-application signal described as “Tesofensine for reduction of body weight in prader-willi patients”. The milestone feed surfaced a patent-application signal described as “Tesofensine for reduction of body weight in prader-willi patients”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION